Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Hepatocellular 5Neoplasms 3Colorectal Neoplasms 3Neoplasm Metastasis 2Liver Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 3Taxes 2Paclitaxel 2Doxorubicin 2trastuzumab biosimilar HLX02 1trametinib 1pegfilgrastim 1nintedanib 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Laparoscopy 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1GSK2141795 1Filgrastim 1Disulfides 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Adenocarcinoma × brivanib × Clear all
NCT00888173 2017-12-06

Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed
45 enrolled 10 charts
GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡